Intermittent fasting strategies for metabolic dysfunction-associated steatotic liver disease: A systematic review and frequentist network meta-analysis of randomized controlled trials
Abu Suilik H, Farid Gadelmawla A, Rifai M, Alhawi M, Ashour A, Abdalshafy H, Abdullah Bataineh O, Rezq H, Bani Hani A, Elkhattib I, Abuelazm M
Clinical nutrition ESPEN · 0 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2026-06-24 · Clin Nutr ESPEN · vol. 75 · pág. 103415
- Editorial
- Elsevier BV
- Citado
- 0 citas · más que el 34% de estudios similares · 0.0× el promedio de su campo
- Referencias
- 43 trabajos
- Acceso
- De pago
- Áreas de investigación
- Dietary Effects on Health · Liver Disease Diagnosis and Treatment · Enhanced Recovery After Surgery
- Palabras clave
- intermittent fasting, non-alcoholic fatty liver disease, time-restricted feeding, alternate-day fasting, 5:2 diet, hepatic steatosis, liver stiffness, insulin resistance, weight loss, adiposity, LDL cholesterol, lifestyle modification
- MeSH
- liver, humans, fatty liver, metabolic diseases, insulin resistance, caloric restriction, fasting, female, randomized controlled trials as topic, non-alcoholic fatty liver disease, intermittent fasting
11 autores
- Husam Abu Suilik🇯🇴Hashemite University
- Ahmed Farid Gadelmawla🇪🇬Menoufia University
- Mohamed K Rifai🇪🇬Menoufia University
- Moayad Alhawi🇯🇴Hashemite University
- Abdellrahman Ashour🇯🇴Hashemite University
- Hassan Abdalshafy🇪🇬Cairo University
- Omar Abdullah Bataineh🇯🇴Jordan University of Science and Technology
- Hazem Salah Rezq🇪🇬Al-Azhar University
- Anas Bani Hani🇯🇴Hashemite University
- Ismail Elkhattib🇺🇸University of Nebraska at Omaha; University of Nebraska Medical Center
- Mohamed Abuelazm🇪🇬Tanta University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition globally. Lifestyle modification through continuous calorie restriction is the cornerstone of management, but long-term adherence is a significant challenge. Intermittent fasting (IF) has been proposed as a more sustainable alternative, though evidence comparing the efficacy of different IF regimens remains limited. This study aimed to compare the effects of various IF strategies on liver and metabolic outcomes in patients with MASLD.
Methods
A systematic review and network meta-analysis of randomized controlled trials (RCTs) was conducted by searching PubMed, EMBASE, Web of Science, Scopus, and CENTRAL to April 2025. We included RCTs that compared different IF regimens-including time-restricted feeding (TRF), alternate-day fasting (ADF), and the 5:2 Diet-among themselves or with non-IF controls in adults with MASLD. A frequentist network meta-analysis was performed, and continuous outcomes were analyzed using mean difference (MD) with 95% confidence intervals (CIs). PROSPERO registration ID: CRD420251068065.
Results
Nineteen RCTs involving 1149 participants were included in the analysis. TRF was the most effective regimen for reducing hepatic steatosis (MD: -23.32 dB/m), followed by the 5:2 Diet; however, none of the IF regimens significantly improved liver stiffness. ADF demonstrated the greatest reductions in body weight, waist circumference, and body fat, and was the only regimen to improve insulin resistance (HOMA-IR) significantly. Both the 5:2 Diet and TRF significantly reduced ALT and AST levels. Additionally, the 5:2 Diet led to a modest but significant reduction in LDL-C.
Conclusion
IF effectively improves hepatic steatosis and key metabolic risk factors in patients with MASLD, but does not affect liver stiffness. The optimal IF strategy may be tailored to patient-specific goals: TRF is superior for reducing liver fat, ADF is most effective for improving adiposity and insulin resistance, and the 5:2 Diet may offer a modest benefit for LDL-C reduction.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.